Report identifies challenges in a growing biosimilars market

A new report from industry analyst Kalorama Information estimates that the global market for biosimilars will be worth almost $6.2 billion by the end of the year.

The document identifies several factors to take note of in assessing the market opportunity for biosimilars, foremost of which is the existence of an established pathway in the EU for biosimilar products, enabling European regulators to approve biosimilar products on the basis of established scientific guidelines and requirements.

While there is more of an established process in Europe, the authors observe that “political changes have provided a regulatory framework permitting biosimilars in the US marketplace since 2015.”